Last 12 months
Inside the activity.
3 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 3 | 0 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2018 Filed Jun 25, 2018 22:22 UTC |
Atlas Venture Fund X, L.P.10% owner
ATLAS VENTURE ASSOCIATES X, L.P.10% owner
Atlas Venture Associates X, LLC10% owner
|
ConversionSeries B Preferred Stock · Derivative | 3,740,239 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017975 · doc4.xml · derivative · entry 6 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 905,188 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Represents the total number of shares of Common Stock received by Atlas Venture Fund X upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F5 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F5 · derivative.underlying_shares: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F2 · ownership.nature: The shares are held directly by Atlas Venture Fund X. The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 22:22 UTC |
Atlas Venture Fund X, L.P.10% owner
ATLAS VENTURE ASSOCIATES X, L.P.10% owner
Atlas Venture Associates X, LLC10% owner
|
ConversionSeries A Preferred Stock · Derivative | 12,580,199 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017975 · doc4.xml · derivative · entry 5 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 3,044,579 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Represents the total number of shares of Common Stock received by Atlas Venture Fund X upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F5 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F5 · derivative.underlying_shares: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F2 · ownership.nature: The shares are held directly by Atlas Venture Fund X. The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 22:22 UTC |
Atlas Venture Fund X, L.P.10% owner
ATLAS VENTURE ASSOCIATES X, L.P.10% owner
Atlas Venture Associates X, LLC10% owner
|
ConversionSeries Seed Preferred Stock · Derivative | 3,333,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017975 · doc4.xml · derivative · entry 4 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 806,711 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Represents the total number of shares of Common Stock received by Atlas Venture Fund X upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F5 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F5 · derivative.underlying_shares: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F2 · ownership.nature: The shares are held directly by Atlas Venture Fund X. The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 22:22 UTC |
Atlas Venture Fund X, L.P.10% owner
ATLAS VENTURE ASSOCIATES X, L.P.10% owner
Atlas Venture Associates X, LLC10% owner
|
ConversionCommon Stock | 905,188 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-017975 · doc4.xml · nonDerivative · entry 3 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,756,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Represents the total number of shares of Common Stock received by Atlas Venture Fund X upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · ownership.nature: The shares are held directly by Atlas Venture Fund X. The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 22:22 UTC |
Atlas Venture Fund X, L.P.10% owner
ATLAS VENTURE ASSOCIATES X, L.P.10% owner
Atlas Venture Associates X, LLC10% owner
|
ConversionCommon Stock | 3,044,579 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-017975 · doc4.xml · nonDerivative · entry 2 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,851,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Represents the total number of shares of Common Stock received by Atlas Venture Fund X upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · ownership.nature: The shares are held directly by Atlas Venture Fund X. The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 22:22 UTC |
Atlas Venture Fund X, L.P.10% owner
ATLAS VENTURE ASSOCIATES X, L.P.10% owner
Atlas Venture Associates X, LLC10% owner
|
ConversionCommon Stock | 806,711 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-017975 · doc4.xml · nonDerivative · entry 1 Atlas Venture Fund X, L.P. · CIK 0001628098 · 10% owner ATLAS VENTURE ASSOCIATES X, L.P. · CIK 0001742766 · 10% owner Atlas Venture Associates X, LLC · CIK 0001742765 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 806,711 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents the total number of shares of Common Stock received by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"), upon the conversion of the Issuer's Series Seed Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · ownership.nature: The shares are held directly by Atlas Venture Fund X. The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 22:15 UTC |
Booth BruceDirector
|
ConversionSeries B Preferred Stock · Derivative | 3,740,239 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017963 · doc4.xml · derivative · entry 6 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 905,188 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Represents the total number of shares of Common Stock received by Atlas Venture Fund X upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F5 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F5 · derivative.underlying_shares: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F2 · ownership.nature: The shares are held directly by Atlas Venture Fund X. The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Dr. Booth is a member of AVA X LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 22:15 UTC |
Booth BruceDirector
|
ConversionSeries A Preferred Stock · Derivative | 12,580,199 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017963 · doc4.xml · derivative · entry 5 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 3,044,579 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Represents the total number of shares of Common Stock received by Atlas Venture Fund X upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F5 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F5 · derivative.underlying_shares: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F2 · ownership.nature: The shares are held directly by Atlas Venture Fund X. The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Dr. Booth is a member of AVA X LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 22:15 UTC |
Booth BruceDirector
|
ConversionSeries Seed Preferred Stock · Derivative | 3,333,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017963 · doc4.xml · derivative · entry 4 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 806,711 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Represents the total number of shares of Common Stock received by Atlas Venture Fund X upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F5 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F5 · derivative.underlying_shares: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F2 · ownership.nature: The shares are held directly by Atlas Venture Fund X. The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Dr. Booth is a member of AVA X LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 22:15 UTC |
Booth BruceDirector
|
ConversionCommon Stock | 905,188 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-017963 · doc4.xml · nonDerivative · entry 3 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,756,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Represents the total number of shares of Common Stock received by Atlas Venture Fund X upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · ownership.nature: The shares are held directly by Atlas Venture Fund X. The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Dr. Booth is a member of AVA X LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 22:15 UTC |
Booth BruceDirector
|
ConversionCommon Stock | 3,044,579 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-017963 · doc4.xml · nonDerivative · entry 2 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,851,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Represents the total number of shares of Common Stock received by Atlas Venture Fund X upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · ownership.nature: The shares are held directly by Atlas Venture Fund X. The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Dr. Booth is a member of AVA X LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 22:15 UTC |
Booth BruceDirector
|
ConversionCommon Stock | 806,711 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-017963 · doc4.xml · nonDerivative · entry 1 Booth Bruce · CIK 0001451612 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 806,711 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents the total number of shares of Common Stock received by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"), upon the conversion of the Issuer's Series Seed Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · ownership.nature: The shares are held directly by Atlas Venture Fund X. The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. Dr. Booth is a member of AVA X LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 18:15 UTC |
Clarus Lifesciences III, L.P.10% owner
Clarus Ventures III GP, L.P.10% owner
Clarus Ventures III, LLC10% owner
|
ConversionSeries B Preferred Stock · Derivative | 2,805,179 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017964 · doc4.xml · derivative · entry 4 Clarus Lifesciences III, L.P. · CIK 0001597143 · 10% owner Clarus Ventures III GP, L.P. · CIK 0001620148 · 10% owner Clarus Ventures III, LLC · CIK 0001664942 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 678,891 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Represents the total number of shares of Common Stock received by Clarus upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. F4 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F4 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F4 · derivative.underlying_shares: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F2 · ownership.nature: The shares are held directly by Clarus. The general partner of Clarus is Clarus Ventures III GP, L.P. ("GPLP"). Clarus Ventures III, LLC, ("LLC") is the general partner of GPLP. Each of Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler, as individual managing directors of the LLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Requadt, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest. Scott G. Requadt is a member of LLC and a member of the Issuer's board of directors. Mr. Requadt disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 18:15 UTC |
Clarus Lifesciences III, L.P.10% owner
Clarus Ventures III GP, L.P.10% owner
Clarus Ventures III, LLC10% owner
|
ConversionSeries A Preferred Stock · Derivative | 9,435,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017964 · doc4.xml · derivative · entry 3 Clarus Lifesciences III, L.P. · CIK 0001597143 · 10% owner Clarus Ventures III GP, L.P. · CIK 0001620148 · 10% owner Clarus Ventures III, LLC · CIK 0001664942 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,283,434 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Represents the total number of shares of Common Stock received by Clarus upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. F4 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F4 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F4 · derivative.underlying_shares: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F2 · ownership.nature: The shares are held directly by Clarus. The general partner of Clarus is Clarus Ventures III GP, L.P. ("GPLP"). Clarus Ventures III, LLC, ("LLC") is the general partner of GPLP. Each of Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler, as individual managing directors of the LLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Requadt, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest. Scott G. Requadt is a member of LLC and a member of the Issuer's board of directors. Mr. Requadt disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 18:15 UTC |
Clarus Lifesciences III, L.P.10% owner
Clarus Ventures III GP, L.P.10% owner
Clarus Ventures III, LLC10% owner
|
ConversionCommon Stock | 678,891 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-017964 · doc4.xml · nonDerivative · entry 2 Clarus Lifesciences III, L.P. · CIK 0001597143 · 10% owner Clarus Ventures III GP, L.P. · CIK 0001620148 · 10% owner Clarus Ventures III, LLC · CIK 0001664942 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,962,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Represents the total number of shares of Common Stock received by Clarus upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · ownership.nature: The shares are held directly by Clarus. The general partner of Clarus is Clarus Ventures III GP, L.P. ("GPLP"). Clarus Ventures III, LLC, ("LLC") is the general partner of GPLP. Each of Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler, as individual managing directors of the LLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Requadt, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest. Scott G. Requadt is a member of LLC and a member of the Issuer's board of directors. Mr. Requadt disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 18:15 UTC |
Clarus Lifesciences III, L.P.10% owner
Clarus Ventures III GP, L.P.10% owner
Clarus Ventures III, LLC10% owner
|
ConversionCommon Stock | 2,283,434 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-017964 · doc4.xml · nonDerivative · entry 1 Clarus Lifesciences III, L.P. · CIK 0001597143 · 10% owner Clarus Ventures III GP, L.P. · CIK 0001620148 · 10% owner Clarus Ventures III, LLC · CIK 0001664942 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,283,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents the total number of shares of Common Stock received by Clarus Lifesciences III, L.P. ("Clarus") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · ownership.nature: The shares are held directly by Clarus. The general partner of Clarus is Clarus Ventures III GP, L.P. ("GPLP"). Clarus Ventures III, LLC, ("LLC") is the general partner of GPLP. Each of Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler, as individual managing directors of the LLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Requadt, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest. Scott G. Requadt is a member of LLC and a member of the Issuer's board of directors. Mr. Requadt disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 18:18 UTC |
Requadt ScottDirector
|
ConversionSeries B Preferred Stock · Derivative | 2,805,179 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017968 · doc4.xml · derivative · entry 4 Requadt Scott · CIK 0001664852 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 678,891 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Represents the total number of shares of Common Stock received by Clarus upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. F4 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F4 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F4 · derivative.underlying_shares: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F2 · ownership.nature: The shares are held directly by Clarus. The general partner of Clarus is Clarus Ventures III GP, L.P. ("GPLP"). Clarus Ventures III, LLC, ("LLC") is the general partner of GPLP. Each of Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler, as individual managing directors of the LLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Requadt, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest. Mr. Requadt is a member of LLC and a member of the Issuer's board of directors. Mr. Requadt disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 18:18 UTC |
Requadt ScottDirector
|
ConversionSeries A Preferred Stock · Derivative | 9,435,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017968 · doc4.xml · derivative · entry 3 Requadt Scott · CIK 0001664852 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,283,434 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Represents the total number of shares of Common Stock received by Clarus upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. F4 · derivative.exercise_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F4 · derivative.expiration_date: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F4 · derivative.underlying_shares: All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date. F2 · ownership.nature: The shares are held directly by Clarus. The general partner of Clarus is Clarus Ventures III GP, L.P. ("GPLP"). Clarus Ventures III, LLC, ("LLC") is the general partner of GPLP. Each of Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler, as individual managing directors of the LLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Requadt, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest. Mr. Requadt is a member of LLC and a member of the Issuer's board of directors. Mr. Requadt disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 18:18 UTC |
Requadt ScottDirector
|
ConversionCommon Stock | 678,891 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-017968 · doc4.xml · nonDerivative · entry 2 Requadt Scott · CIK 0001664852 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,962,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Represents the total number of shares of Common Stock received by Clarus upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · ownership.nature: The shares are held directly by Clarus. The general partner of Clarus is Clarus Ventures III GP, L.P. ("GPLP"). Clarus Ventures III, LLC, ("LLC") is the general partner of GPLP. Each of Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler, as individual managing directors of the LLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Requadt, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest. Mr. Requadt is a member of LLC and a member of the Issuer's board of directors. Mr. Requadt disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any. Read SEC document |
| June 25, 2018 Filed Jun 25, 2018 18:18 UTC |
Requadt ScottDirector
|
ConversionCommon Stock | 2,283,434 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-017968 · doc4.xml · nonDerivative · entry 1 Requadt Scott · CIK 0001664852 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,283,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents the total number of shares of Common Stock received by Clarus Lifesciences III, L.P. ("Clarus") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering. F2 · ownership.nature: The shares are held directly by Clarus. The general partner of Clarus is Clarus Ventures III GP, L.P. ("GPLP"). Clarus Ventures III, LLC, ("LLC") is the general partner of GPLP. Each of Nicholas Galakatos, Dennis Henner, Robert Liptak, Scott Requadt, Nicholas Simon, and Kurt Wheeler, as individual managing directors of the LLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Requadt, Simon and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest. Mr. Requadt is a member of LLC and a member of the Issuer's board of directors. Mr. Requadt disclaims beneficial ownership of such shares, except to the extent of his proportionate pecuniary interest therein, if any. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 20:00 UTC |
Donenberg Phillip B.Director
|
GrantStock Option (Right to Buy) · Derivative | 18,743 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017787 · doc4.xml · derivative · entry 1 Donenberg Phillip B. · CIK 0001238120 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,743 Underlying: Common Stock · 18,743 shares Expires 2028-06-20 F1 · derivative.exercise_date: The shares vest in 36 equal monthly installments following the closing of the Issuer's initial public offering. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.